key: cord-0941944-qwmu5bjp
authors: Kutlu, Omer
title: Can Tenofovir diphosphate be a candidate drug for Sars‐Cov2? First clinical perspective
date: 2020-10-27
journal: Int J Clin Pract
DOI: 10.1111/ijcp.13792
sha: 7d93b1ec7dc2f3b04c3789acd5c75aba94225b36
doc_id: 941944
cord_uid: qwmu5bjp

COVID‐19 pandemic continues to spread across the world in late August 2020. To date, total cases of COVID‐19 exceed 24.5 million including 833.556 deaths according to the WHO data. Governments still taking numerous measures to prevent the spread of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2). The estimate for the basic reproduction number during the early stages of the COVID‐19 outbreak is recently reported as 4.22 ± 1.69 in Europe that shows COVID‐19 has a high transmission rate.

period is reported as 6 (minimum 2, maximum 14) days. 2 Although hydroxychloroquine, oseltamivir, remdesivir, favipiravir have been reported as an anti-SARS-CoV-2 effect, it is still unclear the fully effective protective drug and treatment. 3 A 31-year-old man who has a high fever, chills, loss of smell, and the sore threat presented to the pandemic hospital. He had close contact history with COVID-19 patients in his workplace 6 days ago. The patient was diagnosed as COVID-19 based on the real-time reverse-transcriptasepolymerase chain reaction (RT-PCR) in nasopharyngeal swabs. He had been taken in homequarantine and started orally 2x200 mg hydroxychloroquine. Although he had close contact with his wife without measure in the home his wife did not show any symptoms and signs of COVID-19. 18 days after the first symptoms, the antibody test was performed to the patient and his wife.

The patient had IgG positivity while his wife did not develop antibody positivity including both

This article is protected by copyright. All rights reserved IgM and IgG (Figure 1 ). She had been receiving Tenofovir 245 mg daily for two years for chronic hepatitis B. She did not have any other disease as well as drug history.

SARS-CoV-2 is a positive-sense single-strand RNA virus that has RNA-dependent RNA polymerase property. 4 RNA-dependent RNA polymerase is one of the main target points for the treatment of RNA viruses. Nucleotide analogs act as substrates and inhibit viral polymerases.

Tenofovir diphosphate which is a nucleoside analog reverse-transcriptase inhibitor is an active form of Tenofovir alafenamide that is used for hepatitis B and HIV/AIDS. 5 Recently, it has been shown that nucleoside analogs including 3'-fluoro-3'-deoxythymidine triphosphate, 3'-azido-3'deoxythymidine triphosphate and Tenofovir diphosphate are able to terminate polymerase extension of coronavirus by consolidated with SARS-CoV-2 RNA-dependent RNA polymerase. 6 Given the high reproduction number of SARS-CoV-2 and long-term close contact of the case, it can be speculated that Tenofovir could interfere with the transmission of COVID-19. In accordance with the previous in vitro study, our case is the first clinical report that supports the possible clinical protective effect of Tenofovir. Further randomized clinical studies will illuminate whether Tenofovir may be used as an effective new drug for COVID-19.

The data of this case are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

The reproduction number of COVID-19 and its correlation with public health interventions

Drug discovery strategies for SARS-CoV-2

Coronaviruses-drug discovery and therapeutic options

Approved antiviral drugs over the past 50 years

Nucleotide analogues as inhibitors of SARS-CoV-2

Key Drug Target for COVID-19